The protective effect of platelet-rich plasma administrated on ovarian function in female rats with Cy-induced ovarian damage

Özcan, Pınar; Takmaz, Taha; Tok, Olgu Enis; Islek, Sevde Havva; Yiğit, Esra Nur; Fıçıcıoğlu, Cem

doi:10.1007/s10815-020-01689-7

Cited by 29 publications

(39 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the fact that no association was demonstrated between PRP components and any tumor promotion [79], and that the intense cell proliferation events entailed may induce malignancy was voiced [55]. Although there is no evidence demonstrating any side effects regarding PRP application in the reproductive system, we may be far from reassuring patients on long-term safety [31][32][33][34][35]54,55].…”

Section: Discussionmentioning

confidence: 98%

“…As a result, oxygen, nutrients, and hormonal supply is interrupted and follicular growth is compromised. However, studies indicate that this condition may be reversible and follicular growth could be stimulated when the jeopardized ovarian microenvironment is restored [31][32][33][34][35][53][54][55].…”

Section: Discussionmentioning

confidence: 99%

“…Numerous observations with respect to the angiogenetic structure of the ovaries, along with the vascular activation that is promoted by several platelet-derived factors [56], encouraged our team of experts to test the hypothesis that autologous PRP intraovarian infusion treatment may be able to induce reactivation of dysfunctional ovarian tissue [30]. In fact, it its highlighted that PRP may play an important role in ovarian niche restoration, mainly through the promotion of the physiological processes of angiogenesis, proliferation and growth, apoptosis, inflammation control, as well as cell migration [20,21,54,57]. Considering the regenerative potential of PRP treatment, these pilot studies were conducted aiming to provide data investigating the potential of PRP treatment application toward rejuvenating ovarian function in women presenting with different types of ovarian insufficiency.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women

Sfakianoudis¹,

Simopoulou

Grigoriadis

et al. 2020

JCM

View full text Add to dashboard Cite

Intraovarian platelet-rich plasma (PRP) infusion was recently introduced in the context of addressing ovarian insufficiency. Reporting on its effectiveness prior to adopting in clinical routine practice is imperative. This study aims to provide pilot data regarding PRP application for ovarian rejuvenation. Four pilot studies were conducted on poor ovarian response (POR), premature ovarian insufficiency (POI), perimenopause, and menopause, respectively. Each pilot study reports on thirty patients, 120 participants were recruited in total. All participants provided written informed consent prior to treatment. Primary outcome measures for the POR pilot study were levels of anti-müllerian hormone (AMH), antral follicle count (AFC) and oocyte yield. For the POI, perimenopausal and menopausal pilot studies primary outcome measures were restoration of menstrual cycle, and Follicle Stimulating Hormone (FSH) levels. A significant improvement on the hormonal profile and the ovarian reserve status was noted, along with improved intracytoplasmic sperm injection (ICSI) cycle performance concerning POR participants. Menstruation recovery was observed in 18 out of 30 POI patients, along with a statistically significant improvement on levels of AMH, FSH, and AFC. Similarly, 13 out of 30 menopausal women positively responded to PRP treatment. Finally, menstruation regularity, improved hormonal levels and AFC were reported for 24 out of 30 perimenopausal women. To conclude, PRP infusion appears to convey promising results in addressing ovarian insufficiency.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women

Sfakianoudis¹,

Simopoulou

Grigoriadis

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…A significant improvement was noted in mean follicle number between control vs. PRP injected ovaries, and significantly more high-grade blastocysts were generated following PRP use [20]. Additional animal experiments have found a beneficial (rescue) effect of PRP on ovarian function in female rats with ovarian damage induced by cyclophosphamide, concluding this approach could lead to improved primordial, primary, secondary, and antral follicle counts [21]. section may be divided by subheadings.…”

Section: Ovarian Prp: Veterinary and Human Researchmentioning

confidence: 99%

Appraisal of Experimental Methods to Manage Menopause and Infertility: Intraovarian Platelet-Rich Plasma vs. Condensed Platelet-Derived Cytokines

Sills¹,

Wood²

2021

Preprint

View full text Add to dashboard Cite

The first published description of intraovarian platelet-rich plasma (PRP) appeared in mid-2016, when a new experimental technique was successfully used in adult human ovaries to correct the reduced fertility potential accompanying advanced maternal age. Considering the potential therapeutic scope of intraovarian activated PRP and/or condensed platelet cytokines would likely cover both menopause treatment and infertility, the mainstream response has ranged from skeptical disbelief to welcome astonishment. Indeed, reports of restored menses in menopause (as an alternative to conventional hormone replacement therapy) and healthy term livebirths for infertility patients (either with IVF or as unassisted conceptions) after intraovarian PRP injection continue to draw notice. Yet any proper criticism of ovarian PRP applications will be difficult to rebut given the heterogenous patient screening, varied sample preparations, wide differences in platelet incubation and activation protocols, surgical/anesthesia techniques, and delivery methods. Notwithstanding these features, no adverse events have been reported thus far and ovarian PRP appears well tolerated by patients. Here, early research guiding the transition of ‘ovarian rejuvenation’ from experimental to clinical is outlined. Likely mechanisms are presented to explain results observed in both veterinary and human ovarian PRP research. Current and future challenges for intraovarian cytokine treatment are also discussed.

show abstract

“…El PRP mejora los epitelios aumentando su permeabilidad y oxigenación en el proceso de vascularización sanguínea regenerando los tejidos, causando una bioactivación celular y en consecuencia mejora la Plasma rico en plaquetas en la medicina regenerativa calidad de grosor endometrial, así como su pared se ve beneficiada en los procesos de desarrollo embrionario cuando hay fecundación y regeneración (Abraham et al, 2019) y protege la función ovárica contra daño inducido por Cy en ratas (Ozcan et al, 2020), por lo que se postula que es útil en la medicina reproductiva (Bos-Mikich et al, 2018).…”

Section: Ginecobstetricia Y Urologíaunclassified

Plasma rico en plaquetas como terapia autóloga en la medicina regenerativa: Revisión narrativa

Aguilar¹,

Cáceres²

2020

CTS

View full text Add to dashboard Cite

En las últimas décadas, la terapia de plasma rico en plaquetas (PRP) ha despertado mucha atención en el área de la medicina regenerativa, siendo aplicada a diferentes patologías sistémicas y localizadas. El PRP proporciona diversos factores de crecimiento y proteínas que pueden estimular al proceso de regeneración celular, representa un factor importante para su uso clínico generalizado, en diferentes tejidos en donde el suministro de sangre es lento o limitado y apoya la recuperación, cicatrización, activación biológica de células de defensa, estabilización en la regeneración celular y tisular, teniendo uso clínico en casi todas las especialidades médicas. Esta revisión tiene como objetivo presentar las bases teóricas para la potencial aplicación del PRP y sus factores de crecimiento en tratamientos que buscan una terapia regenerativa por bioestimulación de la aplicación autóloga, en patologías para las cuales aún no existe tratamiento específico. Se revisaron artículos de los últimos 10 años en los buscadores y bases de datos Google Scholar, PubMed y Scopus y se seleccionaron aquellos que pueden ayudar a entender la aplicación de PRP en diversos procesos de regeneración, con miras a utilizarse como un tratamiento alternativo y complementario a pacientes con COVID-19. Se encontró abundante literatura experimental y clínica en el uso de PRP autóloga, en diversos procesos de regeneración, inclusive en neumología e infectología, por lo que amerita comprobar su efecto con protocolos establecidos, en patologías respiratorias severas como apoyo biológico autólogo para activar la respuesta biológica innata de tipo celular.

show abstract

The protective effect of platelet-rich plasma administrated on ovarian function in female rats with Cy-induced ovarian damage

Cited by 29 publications

References 39 publications

Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women

Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women

Appraisal of Experimental Methods to Manage Menopause and Infertility: Intraovarian Platelet-Rich Plasma vs. Condensed Platelet-Derived Cytokines

Plasma rico en plaquetas como terapia autóloga en la medicina regenerativa: Revisión narrativa

Contact Info

Product

Resources

About